Pamoja Is Making a Difference in 2026
Read more on the Pamoja website...
In 2025, a major milestone was reached with the launch of Universiti Malaya Affordable Diagnostics and Therapeutics(UMADT), inspired by the International Affordable Diagnostics and Therapeutics Alliance. Based in Malaysia, UMADT connects academic research, clinical excellence, and industry partners to accelerate affordable therapeutic innovation.
The programme focuses on drug repurposing, clinical trial capacity building, and multinational collaboration, with current priorities including cancer and infectious diseases. Two investigator-led trials — NeoArt-M (colorectal cancer) and NeoArt-CIN (cervical intraepithelial neoplasia) — are already translating research into clinical evaluation using oral artesunate.
Our partner, Pamoja, a Netherlands-based pharmaceutical company and key IA-DATA partner, manufactures the GMP-grade oral artesunate used in these trials and is advancing new artesunate-based combination therapies, reinforcing its commitment to globally accessible, affordable medicines.
BKR's Partner, Pamoja Therapeutics, has summarised recent advances in Artesunate applications on its website!
Check it out to see what good work our partner has been doing!
HomeCyteTM (HomeSep) point-of-care development for sepsis diagnosis with microXlabs
Find out more on our partner’s website!
BKR is co-operating with microxlabs and Fraunhofer Institut to obtain funding for the development of a suite of cost-effective, rapid, near-patient products for triage and monitoring of disease progression using rapid (less than 20-minute) IL-6 test for patients in critical care. Fraunhofer IZI will develop a novel, homogeneous assay which is easier to be automated on a cartridge. HomeCyteTM (microxlab’s device) will perform unique, rapid, on-site developments using patient whole blood and will position the company to move forward with multiple/multiplex biomarkers (CRP, PCT, IL6) for risk stratification into mild, moderate and severely effected sepsis patients. Microfluidic engineering expertise will be the backbone of BKR’s contribution.
BKR's partner, Pamoja Therapeutics, has launched its new website!
Go to Pamoja's website here.
Through the BKR family, a new joint venture has been founded in the Netherlands. The purpose is to support development of affordable therapeutics. There are many indications of neglected diseases and we aim to promote mono- and combination therapies using our expertise in the manufacture of artesunate and pyroniradine.
Your contacts here span two generations of the family: Ashok Krishna, his brother Prof. Dr. Sanjeev Krishna, wife Niraj Krishna and daughter Arti Krishna. Together, we manage all aspects of the business from the management to medical know-how, accounting and marketing. Our international experience spans various industries and the whole is greater than the sum of its parts!
Get in touch with us with your ideas or enquiries:
BKR Gesellschaft für Export und Import was originally established in 1984 and has amassed experience across diverse product types in geographies including Europe, Asia and Africa since then. Moving with the times, there has been a noteworthy recent change: after a long collaboration with the MDV-Group, we have now branched out and refocused our energy and efforts towards exciting new challenges.
As a family company, family values permeate the fabric of our business, and we value trust in our long-term relationships with strategic partners.
